Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 10:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Skin Biopsy Clear all
Completed Not applicable Interventional

Comparison and Outcomes of Endoscopic Ultrasound Liver Biopsies Versus Percutaneous Liver Biopsies

NCT04751045
View directory record Official record
Conditions
Chronic Liver Disease
Interventions
EUS liver biopsy
Procedure
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 28, 2026, 10:12 AM EDT
Terminated Phase 3 Interventional

Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients

NCT00176956
View directory record Official record
Conditions
Dermatitis
Interventions
Skin Biopsy
Procedure
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
Up to 16 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 28, 2026, 10:12 AM EDT
Terminated Phase 2 Interventional Results available

Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

NCT03044353
View directory record Official record
Conditions
Amyloidosis
Interventions
GSK2315698 (CPHPC), GSK2398852 (anti-SAP mAb)
Drug · Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 28, 2026, 10:12 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of SPM™ Topical Cosmetic Application on Skin Appearance, Hydration, and Barrier Support in Healthy Adults

NCT07236736
View directory record Official record
Conditions
Healthy Skin, Skin Hydration
Interventions
Skin biopsy, Corneometer® Measurement, Tewameter® Measurement
Procedure · Other
Lead sponsor
Biocoz Global Pte. Ltd.
Industry
Eligibility
20 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 28, 2026, 10:12 AM EDT
Completed No phase listed Observational

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

NCT00369109
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Pancreatic Cancer
Interventions
biologic sample preservation procedure, immunohistochemistry staining method, laboratory biomarker analysis, biopsy
Other · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2013 · Synced Sep 28, 2026, 10:12 AM EDT
Recruiting Not applicable Interventional

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Surgical Intervention, Conservative Complex Physical Decongestion Therapy
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Not applicable Interventional

Microbial Diversity Between Inflamed and Non-inflamed Skin of Patients With Immune Checkpoint Inhibitor-Induced Dermatitis

NCT04812197
View directory record Official record
Conditions
Genito-Urinary Neoplasm
Interventions
Biospecimen Collection(Punch Biopsy)
Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

NCT06030297
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Diode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System
Procedure · Drug · Diagnostic Test + 1 more
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Withdrawn Phase 2 Interventional

Pilot Safety and Efficacy Study of Isolagen Therapy in Treatment of Restrictive Burn Scars

NCT00620737
View directory record Official record
Conditions
Restrictive Burn Scars of Joint Area
Interventions
Autologous Human Fibroblasts (Isolagen TherapyTM), Placebo
Biological
Lead sponsor
Castle Creek Biosciences, LLC.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
3
States / cities
Boston, Massachusetts • East Meadow, New York • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Sep 28, 2026, 10:12 AM EDT
Active, not recruiting Phase 2 Interventional

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

NCT05947500
View directory record Official record
Conditions
Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma
Interventions
Avelumab, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Tuvusertib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
50
States / cities
Irvine, California • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Completed No phase listed Observational

Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis

NCT00379678
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 28, 2017 · Synced Sep 28, 2026, 10:12 AM EDT
Not yet recruiting No phase listed Observational

Effects of Axatilimab on Skin in Chronic Graft-versus-Host Disease

NCT07728708
View directory record Official record
Conditions
Chronic Graft vs. Host Disease, GVHD, cGVHD, Graft Versus Host Disease in Skin
Interventions
Axatilimab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Withdrawn Early Phase 1 Interventional Accepts healthy volunteers

Skin Immunity Sample Collection Involving Blisters and Biopsies

NCT03921515
View directory record Official record
Conditions
Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Interventions
Blister induction, Skin Biopsies
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
7 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 28, 2026, 10:12 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer

NCT03573648
View directory record Official record
Conditions
Breast Cancer
Interventions
Avelumab, Endocrine therapy, Palbociclib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
4
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 2 Interventional Results available

Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus

NCT00550589
View directory record Official record
Conditions
Anal Cancer, Precancerous Condition
Interventions
cidofovir, DNA methylation analysis, gene expression analysis, polymerase chain reaction, biopsy, histopathologic examination
Drug · Genetic · Procedure
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2015 · Synced Sep 28, 2026, 10:12 AM EDT
Completed No phase listed Observational

DermaSensor Study of Primary Care Physician Use of Elastic-Scattering Spectroscopy (ESS) on Skin Lesions Suggestive of Skin Cancer

NCT06690086
View directory record Official record
Conditions
Skin Cancer
Interventions
Lesion biopsy, DermaSensor Device Use
Procedure · Device
Lead sponsor
DermaSensor, Inc.
Industry
Eligibility
22 Years and older
Enrollment
1,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2024 · Synced Sep 28, 2026, 10:12 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Treatment With Apremilast in Patients With Psoriatic Arthritis

NCT02558361
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Treatment with Apremilast
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma

NCT00847522
View directory record Official record
Conditions
Cancer
Interventions
Fluorescein
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 19, 2017 · Synced Sep 28, 2026, 10:12 AM EDT
Completed No phase listed Observational

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

NCT05230186
View directory record Official record
Conditions
Solid Tumor, Adult
Interventions
Tumor Biopsy
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Los Angeles, California • New Orleans, Louisiana • Morristown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 28, 2026, 10:12 AM EDT
Not listed No phase listed Observational

Scarring in Stratagraft-treated vs. Autograft-treated Burn Wounds: a Clinical and Histological Investigation

NCT04896346
View directory record Official record
Conditions
Burn Scar, Scar
Interventions
Punch biopsy, non-invasive photography, assessments, and measurements
Other
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Not applicable Interventional Results available

Prospective Evaluation of a Surgical Solution for Breast Cancer-Associated Lymphedema

NCT02734979
View directory record Official record
Conditions
Lymphedema, Edema
Interventions
Biobridge and lymph node transfer
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype

NCT04470726
View directory record Official record
Conditions
Superficial Basal Cell Carcinoma, Nodular Basal Cell Carcinoma, Nonmelanoma Skin Cancers
Interventions
AIV001, AIV001 suspension
Drug
Lead sponsor
AiViva BioPharma, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Encinitas, California • Newport Beach, California • San Diego, California + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 28, 2026, 10:12 AM EDT
Completed Phase 1 Interventional

Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer

NCT00004038
View directory record Official record
Conditions
Breast Cancer
Interventions
Ad5CMV-p53 gene, chemotherapy
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Sep 28, 2026, 10:12 AM EDT
Active, not recruiting Phase 2 Interventional

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

NCT02978625
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Apocrine Carcinoma, Carcinoma Arising From Cylindroma, Carcinoma Arising From Spiradenoma, Digital Papillary Adenocarcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Extramammary Paget Disease, Extraocular Sebaceous Carcinoma, Hidradenocarcinoma, Malignant Sweat Gland Neoplasm, Merkel Cell Carcinoma, Microcystic Adnexal Carcinoma, NK-Cell Lymphoma, Unclassifiable, Papillary Adenocarcinoma, Porocarcinoma, Primary Cutaneous Mucinous Carcinoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Merkel Cell Carcinoma, Refractory Mycosis Fungoides, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Skin Squamous Cell Carcinoma, Refractory T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Signet Ring Cell Adenocarcinoma, Skin Adenoid Cystic Carcinoma, Skin Adnexal Carcinoma, Skin Basal Cell Carcinoma, Skin Basosquamous Cell Carcinoma, Skin Keratoacanthoma, Skin Squamous Cell Carcinoma, Squamoid Eccrine Ductal Carcinoma, Squamous Cell Carcinoma of Unknown Primary, Sweat Gland Carcinoma, Trichilemmal Carcinoma, Vulvar Squamous Cell Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Laboratory Biomarker Analysis, Nivolumab, Positron Emission Mammography, Talimogene Laherparepvec
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
36
States / cities
Los Angeles, California • Orange, California • Pasadena, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 28, 2026, 10:12 AM EDT